Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399892 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL21530356 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL26725270 | 0.92 | HSD17B10 (0.41) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL29039402 | 0.92 | HSD17B10 (0.41) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL20399344 | 0.87 | HSD17B10 (0.44) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL20399345 | 0.87 | HSD17B10 (0.44) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL31452738 | 0.84 | HSD17B10 (0.43) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 | |
| SCHEMBL6165737 | 0.84 | ATM (0.46) | SMN1; SMN2HSD17B10OPRD1NPC1ALDH1A1 | |
| SCHEMBL6165730 | 0.84 | ATM (0.46) | SMN1; SMN2HSD17B10OPRD1NPC1ALDH1A1 | |
| SCHEMBL32687093 | 0.83 | HSD17B10 (0.42) | SMN1; SMN2ALOX5APFEN1HSD17B10OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | SMN1; SMN2 1600/4885ALOX5AP 2470/4885FEN1 3561/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | SMN1; SMN2 1600/4885ALOX5AP 2470/4885FEN1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.